ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Fabrication of stimuli-responsive chitosan-coated levofloxacin-incorporated zeolite imidazole nanoparticles for nursing care of wound healing.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rehabilitation for wound care involves a specialized program designed to promote wound healing. This often requires a multidisciplinary team and innovative therapies to enhance healing. However, the discovery of new therapeutics for wound care is limited by issues such as microbial resistance. Levofloxacin (LEV), an antibiotic used to treat bacterial and fungal infections, faces challenges due to its poor bioavailability and limited clinical usage. In this study, we developed a pH-responsive delivery system to effectively release LEV at targeted sites. We successfully encapsulated LEV within multifunctional ZIF-90 nanocrystals coated with a chitosan (CS) polymer. The designed CS@LEV-ZIF-90 NPs enable a pH-responsive antibiotic release mechanism that is particularly effective in acidic environments. This controlled drug release kinetics of ZIF-90 nanocrystals facilitates the rapid delivery of LEV within microbial cells. Our findings demonstrate that the combination of zinc and LEV exhibits a synergistic antibacterial effect, resulting in zones of inhibition of 26 mm against Escherichia coli (E. coli) and 16 mm against Staphylococcus aureus (S. aureus). Moreover, live/dead antibiofilm assays indicate that the CS@LEV-ZIF-90 NPs can eliminate approximately 80% of biofilm-forming infectious pathogens at the lowest tested dose. Additionally, antifungal tests reveal a significant reduction in colony growth against wound-infecting fungi, such as Candida albicans and Aspergillus fumigatus. Importantly, CS@LEV-ZIF-90 NPs exhibit a potential anti-inflammatory effect against LPS-stimulated RAW 264.7 cells, which enhances wound healing and alleviates the inflammation. The biocompatibility investigation confirms that the synthesized CS@LEV-ZIF-90 NPs are non-toxic for clinical applications. Overall, this research highlights the potential of these nanoparticles as an effective and innovative therapeutic option for nursing care of wound healing and rehabilitation in public health.
Indexed as
Identifiers
41504881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.